These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29789639)

  • 21. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.
    Gust J; Taraseviciute A; Turtle CJ
    CNS Drugs; 2018 Dec; 32(12):1091-1101. PubMed ID: 30387077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
    Ritchie DS; Neeson PJ; Khot A; Peinert S; Tai T; Tainton K; Chen K; Shin M; Wall DM; Hönemann D; Gambell P; Westerman DA; Haurat J; Westwood JA; Scott AM; Kravets L; Dickinson M; Trapani JA; Smyth MJ; Darcy PK; Kershaw MH; Prince HM
    Mol Ther; 2013 Nov; 21(11):2122-9. PubMed ID: 23831595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
    Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
    J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
    Schubert ML; Hückelhoven A; Hoffmann JM; Schmitt A; Wuchter P; Sellner L; Hofmann S; Ho AD; Dreger P; Schmitt M
    Hum Gene Ther; 2016 Oct; 27(10):758-771. PubMed ID: 27479233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
    Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
    Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD19 CAR Therapy for Acute Lymphoblastic Leukemia.
    Sadelain M; Brentjens R; Rivière I; Park J
    Am Soc Clin Oncol Educ Book; 2015; ():e360-3. PubMed ID: 25993197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 31. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.
    Valton J; Guyot V; Marechal A; Filhol JM; Juillerat A; Duclert A; Duchateau P; Poirot L
    Mol Ther; 2015 Sep; 23(9):1507-18. PubMed ID: 26061646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Universal CAR T Cells Treat Leukemia.
    Cancer Discov; 2017 Apr; 7(4):342. PubMed ID: 28193774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
    Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
    J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
    Fabrizio VA; Boelens JJ; Mauguen A; Baggott C; Prabhu S; Egeler E; Mavroukakis S; Pacenta H; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Chinnabhandar V; Kunicki M; Goksenin AY; Mackall CL; Laetsch TW; Schultz LM; Curran KJ
    Blood Adv; 2022 Apr; 6(7):1961-1968. PubMed ID: 34788386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR therapy: the CD19 paradigm.
    Sadelain M
    J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
    Singh H; Moyes JS; Huls MH; Cooper LJ
    Cancer Gene Ther; 2015 Mar; 22(2):95-100. PubMed ID: 25591810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
    Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
    Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.